Browse result page of TopicalPdb


Please click on the ID to see detailed information about each entry.

The total number entries retrieved from this search are
IDSequenceNameNature of peptide or cargoAssayTissue permeabilityTissue SamplePUBMED ID
1043β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC>5% of applied doseStratum corneum of human breast skin22890441
1044β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~6% of applied doseStratum corneum of human breast skin22890441
1045β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~1.5% of applied doseStratum corneum of human breast skin22890441
1046β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~5% of applied doseStratum corneum of human breast skin22890441
1047β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~3% of applied doseStratum corneum of human breast skin22890441
1048β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~2% of applied doseStratum corneum of human breast skin22890441
1049β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~7% of applied doseStratum corneum of human breast skin22890441
1050β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~3% of applied doseStratum corneum of human breast skin22890441
1051β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC2% of applied doseStratum corneum of human breast skin22890441
1052β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~11% of applied doseEpidermis of human breast skin22890441
1053β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~9% of applied doseEpidermis of human breast skin22890441
1054β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~3% of applied doseEpidermis of human breast skin22890441
1055β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~10% of applied doseEpidermis of human breast skin22890441
1056β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~7% of applied doseEpidermis of human breast skin22890441
1057β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~5% of applied doseEpidermis of human breast skin22890441
1058β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~12% of applied doseEpidermis of human breast skin22890441
1059β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC>4% of applied doseEpidermis of human breast skin22890441
1060β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~4% of applied doseEpidermis of human breast skin22890441
1061β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC>36% of applied doseDermis of human breast skin22890441
1062β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC>26% of applied doseDermis of human breast skin22890441
1063β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~26% of applied doseDermis of human breast skin22890441
1064β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC25% of applied doseDermis of human breast skin22890441
1065β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC20% of applied doseDermis of human breast skin22890441
1066β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~20% of applied doseDermis of human breast skin22890441
1067β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~26% of applied doseDermis of human breast skin22890441
1068β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC13% of applied doseDermis of human breast skin22890441
1069β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC14% of applied doseDermis of human breast skin22890441
1070β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC9.5% of applied doseAcceptor compartment of Franz diffusion cell22890441
1071β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~7% of applied doseAcceptor compartment of Franz diffusion cell22890441
1072β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC>19% of applied doseAcceptor compartment of Franz diffusion cell22890441
1073β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC21% of applied doseAcceptor compartment of Franz diffusion cell22890441
1074β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC>8% of applied doseAcceptor compartment of Franz diffusion cell22890441
1075β-Ala-HN-acetyl- L -carnosineAntioxidantFranz diffusion cell, HPLC~15% of applied doseAcceptor compartment of Franz diffusion cell22890441
1110YTSLIHSLIEESQNQQ
EKNEQELLELDKWAS
LWNWF
N-acetylated T20Fusion inhibitorReal-time PCRIC50 of 51.2 microM (230 ng/ml; 95% confidence interval, 198 to 267 ng/ml; n 8 independent experiments with 4 donor tissues)Vaginal epithelial sheet19949052
1289GrGDIPASSKGGGGS
rLLLLLLr
RGD peptide matrixActs as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer siteAt each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done.Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 57% (32 patients)Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle8080985
1290GrGDIPASSKGGGGS
rLLLLLLr
RGD peptide matrixActs as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer siteAt each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done.Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 55% (23 patients)Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle8080985
1291GrGDIPASSKGGGGS
rLLLLLLr
RGD peptide matrixActs as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer siteAt each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done.Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 54% (21 patients)Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle8080985
1292GrGDIPASSKGGGGS
rLLLLLLr
RGD peptide matrixActs as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer siteAt each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done.Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 56% (20 patients)Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle8080985
1293GrGDIPASSKGGGGS
rLLLLLLr
RGD peptide matrixActs as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer siteAt each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done.Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 58% (16 patients)Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle8080985
1294GrGDIPASSKGGGGS
rLLLLLLr
RGD peptide matrixActs as a temporary topical synthetic extracellular matrix that presents attachment sites for cells and substitutes for the damaged natural matrix and provides support for cell ingrowth into the ulcer siteAt each visit, the ulcer was cleansed, debrided as needed, traced on acetate film for size determination, and photographed. Ulcer area was determined by computerized planimetry. Regression analysis was also done.Mean percent ulcer closure at study endpoint in ulcers of varying baseline durations ~ 61% (14 patients)Patients were eligible for inclusion in the study if they presented with isolated full-thickness lower leg or ankle ulcers that did not involve bone or tendon and had persisted at least for one month. The peptide matrix is topically applied to the ulcers which were situated at the ankle8080985
1301SYSMEHFRWGKPVα-Melanocyte stimulating hormone (MSH)Controls pigmentary changes in many vertebrates and melanin synthesis within epidermal melanocytes is responsible for melanin pigmentation of the skin, hair, and feathers in man, birds and other mammals.Light and electron microscopy10-7 and 10-8 concentrations turned yellow hair brownMelanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect3684299
1302SYS-Nle-EHfRWGKPV[Nle4, D-Phe7]-alpha-MSHThe analogue is superpotent, being 10- 1000 times more active than the native hormoneLight and electron microscopy10-7 to 10-12 concentrations turned yellow hair brownMelanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect3684299
1303Nle-EHfRWGK[Nle4, D-Phe7]-alpha-MSH4-11Not mentionedLight and electron microscopy10-8 to 10-14 concentrations turned yellow hair brownMelanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect3684299
1304Nle-EHfRWG[Nle4, D-Phe7]-alpha-MSH4-10Not mentionedLight and electron microscopy10-8 to 10-14 concentrations turned yellow hair brownMelanotropin dose was applied on the shaved skin of C57BL/6AY mice which stimulated the yellow hair to turn yellow which was observed at other untouched areas proving systemic effect3684299
1306SYS-Nle-EHfRWGKPV(Nle4, D-Phe7]-α-MSHthe melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of miceElectron microscopy and Light microscopyConcentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application.dorsal trunk of mice (C57BL/6JA y)3624899
1307Nle-EHfFRWGKAc-[Nle4, D-Phe7]-α- MSH4–11-NH2the melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of miceElectron microscopy and Light microscopyConcentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application.dorsal trunk of mice (C57BL/6JA y)3624899
1308Nle-EH-FRWGAc-[Nle4, D-Phe7]-α-MSH4–10-NH2the melanotropin analogs stimulated follicular eumelanogenesis when applied topically to the skin of miceElectron microscopy and Light microscopyConcentrations (10-7 M-10-15 M) induced the emergent hairs to become brown at the sites of application.dorsal trunk of mice (C57BL/6JA y)3624899
1309SYSMEHFRWGKPVα-Melanocyte stimulating hormone (MSH)Controls pigmentary changes in many vertebrates and melanin synthesis within epidermal melanocytes is responsible for melanin pigmentation of the skin, hair, and feathers in man, birds and other mammals.Electron microscopic examinationMinimal effective dose=10-8to10-9M. It stimulated eumelanogenesis in all hair emerging from the areas previously plucked.Posterior dorsum of mice (C57BL/6JA y)3573985
1310SYS-Nle-EHfRWGKPV(Nle4, D-Phe7)-a-MSHThe analogue is superpotent, being 10- 1000 times more active than the native hormoneElectron microscopic examinationMinimal effective dose=10-12M. It is transdermally delivered systemically to hair follicles throughout the body to induce follicular melanogenesis. Microscopic examination revealed eumelanin within hair bulbs by 24 hours after topical application of the analogue.Posterior dorsum of mice (C57BL/6JA y)3573985
1311SYS-Nle-EHfRWGKPV[Nle4, D-Phe7]-alpha-MSHA superpotent(10-1000 times) analogue of alpha-melanocyte stimulating hormone, it causes a very long lasting stimulation of melanocytes in vitro and in vivo, its nonbiodegradeable and it is resistant to enzymatic inactivation by sera, brain enzymes or purified proteolytic enzymes.Frog Skin BioassayPercent positive samples of transdermal delivery :65% (15/23)Full thickness skin samples (approximately 1 and a half" in diameter) were removed from the trunk area of either black or yellow adult C57BL/6JAy mice killed by cervical dislocation2845208